Pharmacological blockade of the CCL2/CCR2 signaling could significantly reduce the inflammatory response and inhibit chronic liver disease progression, suggesting that the CCL2/CCR2 axis may be a promising therapeutic target for treating human liver diseases, especially the prevention of the progression of HCC. This evidence concerns the gene CCR2 and hepatocellular carcinoma.